Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

Inclusion Criteria: * Subjects, ≥2 years of age and ≤17 years of age, of any race or ethnicity * Must have clinical diagnosis of mild to moderate atopic dermatitis (AD) at both Screening and Baseline Visits, defined as IGA score of 2 or 3 (Hanifin and Rajka, Rothe 1980) * Must have AD affecting ≥ 5% total body surface area (TBSA) at Baseline * History of AD for at least 3 months prior to Baseline * Informed consent/assent in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline (21 CFR §50.25\[c\]) and applicable regulations, before completing any study-related procedures Exclusion Criteria: * Use of topical corticosteroids within 7 days prior to Baseline * Use of systemic corticosteroids, topical calcineurin inhibitors, photo-therapy (eg, PUVA, UVB) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to Baseline * Subjects that require systemic therapy for the treatment of atopic dermatitis * Use of systemic anti-infective or antibiotic treatment within 14 days prior to Baseline * Subjects who present with clinical conditions other than AD that may interfere with the evaluation (eg, generalized erythroderma, acne, Netherton's Syndrome, psoriasis) * Secondary infection of AD (bacterial, viral or fungal) within the skin area under study or open skin infections in any area at Baseline * Women of childbearing potential who are lactating or pregnant as determined by urine pregnancy test at Screening. • History of MRX-6 cream 2% sensitivity or to any component of the test article * History of severe anxiety and/or depression; any history of suicide attempt * Subjects with a history of human immunodeficiency virus (HIV) as determined by medical history * Subjects with any screening clinical laboratory result outside the normal range that is clinically relevant in the opinion of an appropriately qualified physician * Subjects who, in the opinion of the Investigator, would be non compliant with the visit schedule or study procedures * Participation in any other investigational trial within 6 weeks of Baseline, or during study conduct * Chronic condition(s) which are either unstable or not adequately controlled * Use of non-sedating anti-histamines within 7 days of first dose or at any time during study conduct * Drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's ability to be compliant with study-related procedures